Phosphorylation and regulation of G-protein-activated phospholipase C-β3 by cGMP-dependent protein kinases

Among the drugs that are known to relax the vascular smooth muscle and regulate other cellular functions, beta -adrenergic agonists and nitric oxide-containing compounds are some of the most effective ones. The mechanisms of these drugs are thought to lower agonist-induced intracellular [Ca2+] by increasing intracellular cAMP and cGMP, activating their respective protein kinases, However, the physiological targets of cyclic nucleotide-dependent protein kinases are not clear, The molecular basis for the regulation of intracellular Ca2+ by signaling pathways coupled to cyclic nucleotides is not well defined. G-protein-activated phospholipase C (PLC-beta) catalyzes the hydrolysis of phosphatidylinositol 4,5-bisphrosphates to generate diacylglycerol and inositol 1,4,5-triphosphate, leading to the activation of protein kinase C and the mobilization of intracellular Ca2+ In this study, we shown that G-protein-activated PLC enzymes are the potential, targets of cGMP-dependent protein kinases (PKG), PKG can directly phosphorylate PLC-beta2 and PLC-beta3 in vitro with purified proteins and in vivo with metabolic labeling. Phosphorylation of PLC-beta leads to the inhibition of G-protein-activated PLC-beta3 activity by 50-70% in COS-7 cell transfection assays. By using phosphopeptide mapping and site-directed mutagenesis, we further identified two key phosphorylation sites for the regulation of PLC-beta3 by PKG (Ser(26) and Ser(1105)). Mutation at these two sites (S26A and S1105A) of PLC-beta3 completely blocked the phosphorylation of PLC-beta3 protein catalyzed by PKG. Furthermore, mutation of these serine residues removed the inhibitory effect of PKG on the activation of the mutant PLC-beta3 proteins by G-protein subunits, Our results suggest a molecular mechanism for the regulation of G-protein-mediated intracellular [Ca2+] by the NO-cGMP-dependent signaling pathway.